

October 2024

| Table 6: Recommended Monitoring After HBV Treatment Initiation in Adults With HIV | | | |
|--|-----------------------------------|-------------------------------|-------------------------------------|
| Laboratory Test | Every 3 Months | Every 6 Months | Every 12 Months |
| HBV DNA | Until HBV DNA is undetectable [a] | After HBV DNA is undetectable | |
| HBeAg | | | Check for HBeAg-negative result [b] |
| Electrolyte panel | | X | |
| Serum creatinine | | X | |
| Urinalysis [c] | | | X |
| Liver function panel [c] | Until HBV DNA is undetectable [a] | After HBV DNA is undetectable | |

Abbreviations: HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.

Notes:

- Undetectable is defined as <10 IU/mL.
- Patients who have been taking anti-HBV treatment for several years may not convert to HBeAg-negative [Singh, et al. 2017].
- See NYSDOH AI guideline [Laboratory Monitoring for Adverse Effects of ART](#).

Reference

Singh KP, Crane M, Audsley J, et al. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. *AIDS* 2017;31(15):2035-52. [PMID: 28692539] <https://pubmed.ncbi.nlm.nih.gov/28692539>